Triple-negative breast cancer (TNBC) represents one of the most clinically demanding malignancies in modern oncology, defined by its highly aggressive phenotype, hormone receptor absence (ER/PR negative), HER2 deficiency, and historically restrictive therapeutic alternatives. The Triple Negative Breast Cancer Treatment Market has witnessed unprecedented evolution throughout recent...